The University of Chicago Header Logo

Connection

Walter M. Stadler to Neoplasms, Hormone-Dependent

This is a "connection" page, showing publications Walter M. Stadler has written about Neoplasms, Hormone-Dependent.
  1. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol. 2005 Nov 01; 23(31):8124-5; author reply 8125-6.
    View in: PubMed
    Score: 0.260
  2. Novel approaches and future directions in castration-resistant prostate cancer. Ann Oncol. 2011 Sep; 22(9):1948-1957.
    View in: PubMed
    Score: 0.093
  3. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 01; 12(5):1556-63.
    View in: PubMed
    Score: 0.066
  4. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol. 2011 Oct 20; 29(30):4022-8.
    View in: PubMed
    Score: 0.024
  5. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 01; 72(2):157-64.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.